Viking Therapeutics stock rating reiterated as Buy by Jefferies

Viking Therapeutics' oral obesity drug VK2735 delivered positive Phase 2 trial results, demonstrating significant weight loss and competitive efficacy against some GLP-1s, yet its stock initially declined amid 'sell the news' dynamics and concerns over tolerability at higher doses. While multiple analysts reiterated Buy ratings, emphasizing potential dosing optimization and robust efficacy, others highlighted competitive challenges against Eli Lilly and tolerability issues. This positions VK2735 at a critical juncture, balancing strong efficacy with market concerns as it advances in the highly competitive obesity treatment landscape.

Analysis

Viking Therapeutics (VKTX) has reported positive topline results from its Phase 2 trial of oral obesity drug VK2735, which demonstrated a statistically significant 12.2% average weight loss at 13 weeks on the highest dose. On a placebo-adjusted basis, the 10-11% weight loss achieved at upper doses is competitive, outperforming some rival treatments. Despite this robust efficacy data, the stock experienced a decline, attributed to a "sell the news" dynamic and persistent investor concerns regarding the drug's tolerability. Specifically, gastrointestinal adverse events and discontinuation rates at higher doses remain a key overhang, potentially impacting its competitive positioning. While Mizuho's analysis suggests Eli Lilly's (LLY) offering is superior, multiple investment firms, including Jefferies, H.C. Wainwright, and Stifel, have reiterated Buy ratings with price targets ranging from $95 to $125. The bull case, articulated by Jefferies, posits that the market is overreacting to the side-effect profile, which could be managed through dosing optimization strategies like a "start low, go slow" approach. The trial's demonstration of dose-dependent weight loss with no plateau effect supports Viking's plans to advance to Phase 2b and oral maintenance studies, but the company's future valuation hinges on balancing this proven efficacy against tolerability challenges in a highly competitive market.

Key Decisions for Investors

• Investors should weigh the drug's compelling efficacy, which surpassed some competitors, against the significant risk posed by its tolerability profile and high discontinuation rates at key doses.
• The post-announcement stock drop could present a buying opportunity for those confident that dosing optimization in future trials will mitigate side-effect concerns, aligning with the bullish analyst consensus.
• Closely monitor future clinical updates, particularly the design of the Phase 2b study and any data on improved patient tolerance, as this will be the primary catalyst for re-rating the stock against established competitors like Eli Lilly.
• Consider the high-conviction Buy ratings from multiple analysts with price targets substantially above the current price, but balance this against the clinical execution risk and the bearish counterpoint regarding competitive inferiority on some metrics.